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Abstract
Purpose The aim of this study was to compare patient
characteristics and midterm outcomes after RFA for unre-
sectable Hepatocellular carcinoma (HCC) in Asian and
European cohorts.
Materials and Methods The study was based on retro-
spective analysis of 279 patients (mean 64.8 ± 12.1 years;
208 males) treated with RFA for de novo HCC in tertiary
referral centers in Singapore and the Netherlands, with
median follow-up of 28.2 months (quartiles:
13.1–40.5 months). Cumulative incidence of recurrence
and death were analyzed using a competing risk model.
Results Age was higher in the Asian group: 66.5 versus
60.1 years (p\ 0.0001). The most common etiology was
hepatitis B in the Asian group (48.0 %) and alcohol-in-
duced cirrhosis in Europeans (54.4 %); p\ 0.001. Asian
patients had less advanced disease: 35.5, 55.0, and 3.0 %,
respectively, had BCLC 0, A, and B versus 21.5, 58.2, and
15.2 % in the European group (p = 0.01). The cumulative
incidences of recurrence in the Asian group at 1, 2, 3, and
5 years were 37.0, 56.4, 62.3, and 67.7 %, respectively,
compared to 32.6, 47.2, 49.7, and 53.4 % in the European
group (p = 0.474). At 1, 2, 3, and 5 years, the cumulative
incidence rates of death in the Asian group were 2.0, 3.9,
4.9, and 4.9 %, respectively, corresponding to 7.7, 9.2,
14.1, and 21.0 % in the European group (p = 0.155).
Conclusion Similar short-term treatment outcomes are
achieved with RFA in HCC patients in the South-East
Asian and Northern-European populations. Midterm
recurrence and death rates differ between the groups as a
result of differences in baseline patient characteristics and
patient selection. Our study provides insight relevant to the
design of future international studies.
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Introduction
Hepatocellular carcinoma (HCC) is a heterogenous condi-
tion with multiple variables affecting the course of the dis-
ease. The prognosis is not only determined by the tumor
burden, but also by the liver function and performance status
of a patient. In order to have stratification and prognostica-
tion ability, most staging systems have incorporated various
prognostic factors [1–6]. The Barcelona Clinic Liver Cancer
(BCLC) classification system is the most widely adopted
staging system for HCC worldwide and is endorsed by the
European Association for the Study of the Liver (EASL) and
American Association for the Study of Liver Disease [7, 8].
The Asian Pacific Association for the Study of the Liver
(APASL) guidelines are based on results from many of the
randomized controlled trials and cohort studies that were
also used to devise the BCLC schedule, and both guidelines
use similar eligibility criteria for RFA [9]. Despite adherence
to similar treatment guidelines, outcomes in daily clinical
practice are unlikely to be the same in different parts of the
world as a result of geographic differences in characteristics
and etiology of HCC. In East-Asia, the incidence rates of
HCC are high, and most HCC cases are attributable to
chronic hepatitis B infection [7, 10]. In Northern-European
countries, HCC is not prevalent, and chronic hepatitis C and
alcohol-induced liver disease are the most dominant pre-
disposing risk factors [7, 10].
Prospective clinical trials have been essential in the
development of treatment guidelines, but often only recruit
patients from a particular region and according to strict
eligibility criteria. Real-world observational studies are
needed to provide insight into how the implementation of
HCC guidelines has affected patient care in different geo-
graphic regions. The aim of our descriptive study was to
compare the patient characteristics and midterm outcomes
after RFA for unresectable, de novo HCC in Asian and
European patient cohorts. In this retrospective study, the
cumulative incidence rates of recurrence and death after
RFA were analyzed in large centers both in South-East
Asia and Northern Europe.
Methods
Patients
We conducted a retrospective analysis of a patient cohort in
a high-volume hospital in Singapore and the Netherlands.
Both institutions were tertiary referral centers with dedi-
cated care for hepato-biliary diseases and liver transplant
programs. The local medical ethics committee of both
institutions approved the retrospective study, and informed
consent was waived for the analysis. Between January
2009 and March 2014, 442 consecutive patients were
treated with percutaneous RFA for unresectable HCC in
the radiology department of one of the two centers. Of the
442 patients, 163 had undergone previous HCC treatment,
i.e., ablation, resection, transplantation or transarterial
chemoembolization, and these were excluded from the
analysis. All remaining 279 patients [mean age ± standard
deviation (SD): 64.8 ± 12.1 years; 208 males] were treated
with RFA because of newly diagnosed HCC. The diagnosis
was based on either tumor histology (n = 30) or on radi-
ological imaging criteria according to guidelines by the
EASL or the APASL (n = 249) [7, 9]. For radiological
confirmation of the diagnosis, multiphase contrast-en-
hanced computed tomography (CECT) and/or dynamic
gadolinium-enhanced magnetic resonance imaging (GE-
MRI) was used. Arterial hyperenhancement of a lesion
with wash-out in the delayed phase was considered to be
diagnostic of HCC in patients with liver cirrhosis or
chronic hepatitis B/C.
Similar eligibility criteria were used in both centers for
local ablation, and these were in accordance with the
BCLC and APASL treatment guidelines: a single tumor
measuring B5 cm or a maximum of 3 HCCs measur-
ing B3 cm each and Child Pugh A or B status (7,9). In
exceptional cases, RFA was offered also outside BCLC
and APASL criteria. In patients with two tumors, RFA
was considered if only one HCC measured more than
3 cm and no more than 5 cm. Patients with Child Pugh C
who were on the waiting list for liver transplantation
could undergo RFA as a bridging therapy to transplanta-
tion. Contra-indications for RFA were significant and
uncorrectable coagulopathy, extrahepatic metastasis, or
macrovascular invasion, and severe liver dysfunction
(Child Pugh C) in a patient not eligible for liver
transplantation.
Radiofrequency Ablation
All patients gave informed consent prior to treatment.
Percutaneous RFA was performed using ultrasound and/or
CT guidance. In the European center, procedures were
performed under general anesthesia. Local anesthesia and
conscious sedation with midazolam and fentanyl were used
in the Asian center.
Both centers used similar RFA equipment: either a
single electrode was used (3-cm-exposed tip Cooltip (Co-
vidien, Gosport Hamspire, UK) or multiple electrodes with
a switch-control system (3- or 4-cm-exposed tip Cooltip).
M. C. Burgmans et al.: Differences in Patient Characteristics and Midterm... 1709
123
Ablation was performed for 12 (single Cooltip electrode)
or 16–20 min (multiple Cooltip electrodes) using standard
impedance controlled ablation. In the European center,
CECT was performed immediately after ablation on a
spiral CT (Aquilion 16, Toshiba, Tokyo, Japan). If this
CT showed residual tumor enhancement, immediate re-
ablation was performed. In the Asian center, CECT was
performed 1 day after ablation (Aquillion 64, Toshiba,
Tokyo, Japan). If the CECT showed residual tumor
enhancement, re-ablation was performed during the same
or subsequent admission, dependent on the patient’s
preference.
Follow-Up
All patients were scheduled for follow-up examinations
every 3 months after RFA, including liver function tests
and multiphase CECT or dynamic GE-MRI. In the Euro-
pean center, these examinations were also performed at
6 weeks after RFA.
Recurrence was defined as local tumor progression
(LTP) and/or a new intrahepatic tumor distant from the
treated tumor. Recurrence was distinguished from incom-
plete ablation. Tumor enhancement on the CECT per-
formed immediately or 1 day after RFA, was classified as
incomplete ablation and treated with repeated RFA until
complete radiological ablation was achieved. Patients were
followed until last follow-up date, death, or till the end of
the study.
The median follow-up for all patients was 28.2 months
(quartiles: 13.1–40.5 months).
Statistical Analysis
Comparisons between the two groups were done by student
t-test for continuous variables and Pearson Chi-Square test
for categorical variables using two-sided tests. A compet-
ing risk model with recurrence and death as competing
events was used to estimate the cumulative incidence of
recurrence and death per center. To study the impact of
prognostic factors on recurrence, the cause-specific hazard
ratios were estimated by employing a Cox proportional
hazard regression model with transplantation as time-de-
pendent risk factor [11]. A Cox’s proportional hazard
model was employed to study the association between risk
factors and overall survival with recurrence and trans-
plantation as time-dependent risk factors. A difference was
considered significant when p\ 0.05. The statistical
analyses were performed using SPSS 21 (IBM, Armonk,
NY, USA). The competing risks analysis was performed in




Baseline demographics of all patients are shown in
Table 1. The median age of patients in the Southeast Asian
group was slightly higher than that of the Northern Euro-
pean patients (p\ 0.0001). Statistically significant differ-
ences between the patient groups were also seen in
underlying liver disease and BCLC stage (p\ 0.0001 and
p = 0.01, respectively). In the European patients, alcoholic
liver disease was most prevalent (54.4 %) followed by
hepatitis C (22.7 %), whereas the majority of Asian
patients suffered from chronic hepatitis B (48.0 %). The
percentage of patients without underlying liver disease was
much higher in the Asian group compared with the Euro-
pean group: 19.0 versus 6.3 %. The Asian group had a
higher percentage of patients with BCLC very early stage:
35.5 versus 21.5 % in the European group. Both the per-
centages of patients with BCLC early stage and interme-
diate stage were higher in the European group: 58.2 and
15.2 %, respectively, versus 55.0 and 3.0 % in the Asian
group. These differences in BCLC stage may be explained
by the dissimilarities in Child Pugh class, number of
tumors, and maximal tumor diameter between the two
groups. In the Asian group, a higher percentage of patients
had Child Pugh A status (68.5 vs. 60.8 %), a single tumor
(77.0 vs. 67.1 %), and the mean maximal diameter of the
largest tumor was smaller (23.7 ± 11.3 vs.
26.8 ± 12.6 mm). The differences in Child Pugh status,
tumor number and tumor size did not reach statistical
significance.
Treatment Outcome
In 269 patients (96.4 %), technical success was achieved
after a single RFA procedure. In the remaining 10 patients,
a second ablation procedure was needed to achieve tech-
nical success.
The cumulative incidence of recurrence showed a sim-
ilar trend in both the Asian and European groups during the
first 1.5 years after RFA (see Fig. 1). At 6, 12, and
18 months, the cumulative incidence rates for recurrence in
the Asian group were equal to 25.5 % (95 % CI
19.5–31.6), 37.0 % (95 % CI 30.3–43.8), and 49.1 %
(95 % CI 41.9–56.2), respectively, compared to 24.1 %
(95 % CI 14.7–33.5), 32.6 % (95 % CI 22.0–43.2), and
45.5 % (95 % CI 33.8–57.2), respectively, in the European
group. The cumulative incidence of recurrence was higher
in the Asian group at 2, 3, and 5 years: 56.4 % (95 % CI
49.1–63.8), 62.3 % (95 % CI 54.7–69.8), and 67.7 %
(95 % CI 58.6–76.7), respectively, compared to 47.2 %
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(95 % CI 35.4–59.0), 49.7 % (95 % CI 37.5– 62.0), and
53.4 % (95 % CI 40.2–66.6), respectively, in the European
group. The difference between the cumulative incidences
of recurrence for the two groups was not significant
(p = 0.474).
The cumulative incidence of death was higher in the
European population compared with the Asian group
(Fig. 1). At 1, 2, 3, and 5 years, the cumulative incidence
rates of death were 2.0 % (95 % CI 0.06–4.0), 3.9 %
(1.0–6.7), 4.9 % (1.5–8.3), and 4.9 % (1.5–8.3), respec-
tively, in the Asian group and 7.7 % (1.8–13.6), 9.2 %
(2.7–15.8), 14.1 % (5.1–23.1), and 21.0 % (9.0–33.1) in
the European group. The differences in cumulative death
between the two groups did not reach statistical signifi-
cance (p = 0.155).
Prognostic Factors Associated with the Risk
of Recurrence
A maximal tumor diameter[3 cm and tumor number[1
were independent risk factors for recurrence after RFA (see
Table 2). The cause-specific hazard ratio (csHR) was equal
to 1.568 (95 % CI 1.083–2.271) for patients with
HCCs[3 cm. Patients with more than 1 tumor were 1.5
Table 1 Baseline characteristics of 279 patients treated with RFA for de novo HCC
Asia–Pacific; n = 200 (%) European; n = 79 (%) Total; n = 279 (%) p value
Age (years), mean ± SD 66.5 ± 10.7 60.1 ± 14.3 64.8 ± 12.1 <0.0001




HBV 96 (48.0) 7 (8.9) 103 (36.9)
HCV 26 (13.0) 18 (22.7) 44(15.8)
Alcohol 21 (10.5) 43 (54.4) 64 (22.9)
NASH 11 (5.5) 3 (3.8) 14 (5.0)
Cryptogenic 38 (19.0) 5 (6.3) 43 (15.4)
Others 3 (3.8) 11 (3.9)
AFP (ng/mL), mean ± SD 141.4 ± 753.3a 346.9 ± 1600.6b 212.7 ± 1122.7 0.289
Child pugh class 0.248
A 137 (68.5) 48 (60.8) 185 (66.3)
B 49 (24.5) 27 (34.2) 77 (27.6)
C 14 (7.0) 4 (5.0) 17 (6.1)
Number of tumors 0.139
1 154 (77.0) 53 (67.1) 207 (74.2)
2 39 (19.5) 24 (30.4) 63 (22.6)
3 7 (3.5) 2 (2.5) 9 (3.2)
Maximal diameter largest tumor (mm), mean ± SD 23.7 ± 11.3 26.8 ± 12.6 24.9 ± 12.5 0.85
Maximal diameter largest tumor 0.106
\10 mm 9 (4.5) 0 (0.0) 9 (3.2)
10 to\20 mm 84 (42.0) 26 (31.9) 110 (39.4)
20 to 30 mm 61 (30.5) 26 (32.9) 87 (31.2)
[30 mm 46 (23.0) 27 (34.2) 73 (26.1)
BCLC stage 0.01
0 71 (35.5) 17 (21.5) 88 (31.5)
A 110 (55.0) 46 (58.2) 156 (55.9)
B 6 (3.0) 12 (15.2) 18 (6.5)
C 0 (0.0) 0 (0.0) 0 (0.0)
D 13 (6.5) 4 (5.0) 17 (6.1)
Statistically significant p values are given in bold (p\ 0.05)
HBV hepatitis B virus, HCV hepatitis C virus, NASH nonalcoholic steatosis hepatitis, BCLC Barcelona Clinic Liver Cancer
a 55 missing
b 2 missing
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times more likely to develop recurrence than patients with
a single tumor (HRc 1.494 (95 % CI 1.031–2.163). Liver
transplantation had a significant protective effect on tumor
recurrence (HRc 0.065; 95 % CI 0.009–0.480).
Cox Regression Model for Overall Survival
Child Pugh B/C status and recurrence were independent
risk factors for death after RFA (see Table 3). The hazard
ratios (HRs) for Child Pugh B and C were equal to 2.924
(95 % CI 1.582–5.404) and 4.824 (95 % CI 2.100–11.083),
respectively, with Child Pugh A status as reference cate-
gory. The HR was almost 5 times increased in patients with
recurrence compared with patients without recurrence (HR
4.524; 95 % CI 2.438–8.395). An increased HR of death
was found in patients with either hepatitis C or alcohol-
induced liver disease compared to those with hepatitis B,
but the differences were nonsignificant.
Liver transplantation had a protective effect, though not
statistically significant (HR 0.805; 95 % CI 0.318–2.036).
Further Treatment
Table 4 provides an overview of consecutive treatments
that were administered in patients with recurrent disease.
No significant differences were seen between the two
groups other than the higher proportion of patients in the
European group receiving a liver transplantation. In the
European group, 44.3 % (n = 35) of patients eventually
underwent liver transplantation compared to 3.0 % in the
Asian group (n = 6) (p\ 0.0001).
Discussion
Our study provides insight into the differences in baseline
characteristics and treatment outcomes between a South-
East Asian and a Northern-European cohort of patients
undergoing RFA for de novo HCC. The differences
observed may have implications for clinical management
and the design of large multicenter, international studies.
Our study confirms that hepatitis B is the leading cause
of HCC in South-East Asia, whereas most HCC cases in
the Northern Europe are related to alcohol or hepatitis C.
This is well known from the literature [7, 10]. The higher
Fig. 1 Cumulative incidence of recurrence and death in the South-
East Asian and Northern European patient group
Table 2 Cause-specific hazard ratios to evaluate the effect of prog-
nostic factors on risk of recurrence (multivariate analysis)
csHR 95.0 % CI for HR p value
Lower Upper
Female (reference male) .844 .567 1.256 0.403
Child Pugh A (reference) 0.480
Child Pugh B .795 .535 1.181 0.256
Child Pugh C .810 .412 1.591 0.540
Largest tumor diameter[3 cm 1.568 1.083 2.271 0.017
Tumor number[1 1.494 1.031 2.163 0.034
Hepatitis B (reference) 0.739
Hepatitis C .857 .497 1.477 0.578
Alcohol-induced 1.175 .702 1.967 0.538
Other 1.100 .692 1.750 0.686
South-East Asian centera .978 .609 1.568 0.925
Liver transplantation .065 .009 .480 0.007
Statistically significant p values are given in bold (p\ 0.05)
csHR cause-specific hazard ratio, CI confidence interval
a The Northern-European Center was used as the reference center
Table 3 Hazard ratios to evaluate the effect of prognostic factors on
overall survival (multivariate analysis)
HR 95.0 % CI for HR p value
Lower Upper
Female (reference male) .968 .491 1.911 0.926
Child Pugh A (reference)
Child Pugh B 2.924 1.582 5.404 0.001
Child Pugh C 4.824 2.100 11.083 0.000
Largest tumor diameter[3 cm 1.326 .714 2.462 0.372
Tumor number[1 .679 .355 1.299 0.242
Hepatitis B (reference) 0.399
Hepatitis C 1.573 .697 3.549 0.275
Alcohol-induced 1.234 .554 2.747 0.607
Other .776 .326 1.845 0.566
South-East Asian center .531 .269 1.049 0.068
Recurrence (time-dependent) 4.524 2.438 8.395 0.000
Liver transplantation .805 .318 2.036 0.647
Statistically significant p values are given in bold (p\ 0.05)
HR hazard ratio, CI confidence interval
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percentage of patients without known risk factors in the
Asian study group is also consistent with previous reports
[14].
In the Asian group, the number of tumors as well as
Child Pugh score was lower compared with the European
group. These observed dissimilarities between the two
groups may, in part, reflect differences in patient selection.
First of all, differences in screening between the Nether-
lands and Singapore may have resulted in detection of
tumors at an early stage in the Asian group. In both
countries, six-monthly screening with ultrasonography was
common practice during the study period, but the higher
incidence of HCC in Asia is likely to result in higher
awareness and better adherence to the screening program
by Singaporean doctors and patients. Second, differences in
baseline characteristics may be a result of differences in the
EASL and APASL guidelines. According to the APASL
guidelines, the diagnosis of HCC can be made regardless of
the size of a lesion, if a lesion has typical arterial
enhancement and portovenous ‘wash-out’ on diagnostic
imaging. This is different from the EASL guidelines that
state that noninvasive criteria only apply in patients with
typical lesions[1 cm. The difference in diagnostic criteria
between the APASL and EASL guidelines explains the
difference in baseline tumor size between the Asian and
European groups in our study. In the Asian group, 9
patients had a maximal tumor diameter of\1 cm, whereas
all European patients had a tumor larger than 1 cm. This is
also reflected by the smaller mean tumor diameter of
patients in the Asian group compared to that of the Euro-
pean patients (23.7 ± 11.3 vs. 26.8 ± 12.6 respectively).
As the noninvasive diagnostic accuracy is lower in
lesions\1 cm, there is an increased risk of a false-positive
diagnosis of HCC in the Asian group in our study. It is
unlikely, however, that this had a significant impact on the
results of our study, as only 4.5 % of patients in the Asian
group had lesions\1 cm.
There is considerable overlap between the BCLC and
APASL treatment algorithms with regard to selection of
patients for RFA. According to both algorithms, eligible
candidates are Child Pugh A/B patients with a single
tumor B5 cm or up to three nodules of B3 cm each and
the absence of vascular invasion of extrahepatic disease
(the EASL guidelines do not clearly give a maximal
diameter for a solitary tumor, but 5 cm is generally con-
sidered the limit beyond which RFA is associated with
unacceptable high recurrence rates). The EASL and
APASL guidelines both recommend RFA as an alternative
to resection for patients not suitable for surgery, but do not
use the same criteria to select surgical candidates [15]. The
EASL guidelines recommend resection for patients with a
single tumor with very well-preserved liver function,
defined as normal bilirubin with either hepatic vein pres-
sure gradient\10 mmHg or platelet count C100 9 109/L.
According to the APASL guidelines, surgical resection
should be considered for single or multifocal disease,
anatomically resectable, and with satisfactory liver func-
tion reserve without strict cutoff values. As a result of the
more conservative criteria for resection in the EASL
guidelines, patients may have been referred for ablation in
the European center, whereas the same patients may still
have been surgical candidates in the Asian institution. This
may have contributed to a higher percentage of patients in
the European group with Child Pugh B status and[1
tumor. Following the APASL guidelines, decisions on
resectability in South-East Asia are more contingent on age
and functional capacity of a patient. This may also explain
the significantly higher age of patients in the Asian cohort.
The differences in cumulative incidence of recurrence
and death between the Asian and European groups are
likely related to a multitude of variables, such as patient
selection, baseline patient characteristics, pathogenesis and
histopathology of tumors, differences in clinical manage-
ment, and treatment of underlying liver disease. Patients in
the European group had an insignificant higher midterm
cumulative incidence of death. As the recurrence rate in the
European patients was not higher than that in the Asian
patients, the poorer survival rate is probably attributable to
factors other than disease progression. It is likely that the
significantly higher baseline Child Pugh score had a neg-
ative impact on survival. A higher Child Pugh score has
been shown to be associated with poorer overall survival in
Table 4 Summary of second-






n = 97 (48.5 %)
European group;
n = 54 (68.4 %)
p value
Resection 8 (4.0) 2 (2.5) 0.552
RFA 68 (34.0) 21 (26.6) 0.231
TACE/TARE 35 (17.5) 13 (16.5) 0.835
Liver transplantation 5 (2.5) 35 (44.3) <0.0001
Sorafenib 3 (1.5) 4 (5.1) 0.89
Statistically significant p value is given in bold (p\ 0.05)
TACE transarterial chemoembolization, TARE transarterial radioembolization
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previous studies [16–23]. The lower Child Pugh score may
also reflect a difference between the two groups in the
proportion of patients with cirrhosis, as the development of
HCC in the absence of cirrhosis tends to be more common
in Asian patients. Another factor could be the differences
in therapeutic options for the underlying liver disease.
Antiviral agents such as lamivudine, adefovir dipivoxil, or
entecavir may improve overall survival after RFA in hep-
atitis B patients, whereas therapeutic options for hepatitis C
and alcohol-induced liver cirrhosis were limited during the
study period [24, 25]. Finally, differences in molecular
pathogenesis of HCC between regions and races may result
in differences in outcome [26].
Although previous studies have shown that liver trans-
plantation improves survival in patients with HCC, such a
survival benefit was not found in our study [27]. Trans-
plantation did have a significant protective effect on tumor
recurrence, but the protective effect on survival did not
reach statistical significance. This is likely to be related to
the relatively small number of patients that were trans-
planted in our study (14.3 %).
Our study findings are of importance when interpreting
published studies on RFA in HCC patients. Comparison of
studies that have been conducted in different parts of the
world is complicated by the differences in patient charac-
teristics, selection, and clinical management. Results
obtained in an Asian population cannot be extrapolated to a
European population without notion of these differences,
and vice versa. Our results may also have important
implications for the design of new international studies.
Based on our results, the impact of RFA on survival may be
more difficult to determine in a Northern-European popu-
lation than in a South-East Asian cohort as factors other
than tumor progression play a more important role in the
first group of patients. European patients eligible for RFA
are likely to have risk factors other than tumor recurrence
that are associated with poorer survival, such as hepatitis C
or alcohol-induced liver cirrhosis, and higher BCLC stage.
To demonstrate survival benefit of RFA in a group of
European patients with unresectable HCC, one may thus
need a larger sample size than that in an Asian patient
group.
Our descriptive study has several limitations. The first
limitation is the retrospective design of the study. Second,
the numbers of centers included in our analysis are limited,
and therefore the data may not be representative for all
centers in the geographic regions that were compared.
Third, some predicting factors that may have have been
different between the two cohorts were not analyzed, for
example, co-morbidity, tumor histology, and antiviral
treatment of hepatitis. Fourth, a small number of patients in
the Asian and European groups were treated outside
APASL and EASL criteria, respectively. This may have
caused differences between the groups that are not
attributable to differences in the regional guidelines.
Finally, we did not analyze the cause of death. The poorer
survival rate in the European patients may have been
related to causes other than progression of tumor or
underlying liver disease. It is not unlikely that the pro-
portions of patients with tobacco abuse and poor nutritional
status were higher in the European group given the higher
prevalence of alcohol abuse.
In conclusion, the baseline characteristics of patients
treated with RFA for de novo HCC differ between
Northern-European and South-East Asian patients. Despite
these differences, similar short term treatment outcomes
are achieved by applying regional recommendations for
RFA in HCC patients. Midterm recurrence and death rates
differ between the two groups, and this may be explained
by differences in underlying liver disease, screening, and
the more conservative approach to resection in European
countries.
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